研究者詳細 - 寺井　崇二

論文 - 寺井　崇二

分割表示 1,104 件中 201 - 220 件目／全件表示 >>

病態に基づく肝疾患医療連携の今後肝炎医療コーディネーターと連携した院内における肝炎ウイルス陽性者の拾い上げ

荒生祥尚, 薛徹, 寺井崇二

日本消化器病学会雑誌 119 ( 臨増総会 ) A229 - A229 2022年3月

重症急性膵炎後Walled-off necrosisの経過に対する抗菌薬投与の影響

五十嵐聡, 林和直, 寺井崇二, 小川光平

日本消化器病学会雑誌 119 ( 臨増総会 ) A344 - A344 2022年3月

栄養・代謝機能と消化器疾患の病態解明と治療膵臓癌における脂肪酸分画の臨床的意義についての検証

小川光平, 林和直, 寺井崇二

日本消化器病学会雑誌 119 ( 臨増総会 ) A174 - A174 2022年3月

Cyclin D1 Binding Protein 1 Responds to DNA Damage through the ATM-CHK2 Pathway. 国際誌

Yusuke Niwa, Kenya Kamimura, Kohei Ogawa, Chiyumi Oda, Yuto Tanaka, Ryoko Horigome, Masato Ohtsuka, Hiromi Miura, Koichi Fujisawa, Naoki Yamamoto, Taro Takami, Shujiro Okuda, Masayoshi Ko, Takashi Owaki, Atsushi Kimura, Osamu Shibata, Shinichi Morita, Norihiro Sakai, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Shuji Terai

Journal of clinical medicine 11 ( 3 ) 2022年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

Cyclin D1 binding protein 1 (CCNDBP1) is considered a tumor suppressor, and when expressed in tumor cells, CCNDBP1 can contribute to the viability of cancer cells by rescuing these cells from chemotherapy-induced DNA damage. Therefore, this study focused on investigating the function of CCNDBP1, which is directly related to the survival of cancer cells by escaping DNA damage and chemoresistance. Hepatocellular carcinoma (HCC) cells and tissues obtained from Ccndbp1 knockout mice were used for the in vitro and in vivo examination of the molecular mechanisms of CCNDBP1 associated with the recovery of cells from DNA damage. Subsequently, gene and protein expression changes associated with the upregulation, downregulation, and irradiation of CCNDBP1 were assessed. The overexpression of CCNDBP1 in HCC cells stimulated cell growth and showed resistance to X-ray-induced DNA damage. Gene expression analysis of CCNDBP1-overexpressed cells and Ccndbp1 knockout mice revealed that Ccndbp1 activated the Atm-Chk2 pathway through the inhibition of Ezh2 expression, accounting for resistance to DNA damage. Our study demonstrated that by inhibiting EZH2, CCNDBP1 contributed to the activation of the ATM-CHK2 pathway to alleviate DNA damage, leading to chemoresistance.

DOI： 10.3390/jcm11030851

PubMed

researchmap

A novel prostaglandin I2 agonist, ONO-1301, attenuates liver inflammation and suppresses fibrosis in non-alcoholic steatohepatitis model mice. 国際誌

Satoko Motegi, Atsunori Tsuchiya, Takahiro Iwasawa, Takeki Sato, Masaru Kumagai, Kazuki Natsui, Shunsuke Nojiri, Masahiro Ogawa, Suguru Takeuchi, Yosiki Sakai, Shigeru Miyagawa, Yoshiki Sawa, Shuji Terai

Inflammation and regeneration 42 ( 1 ) 3 - 3 2022年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: ONO-1301 is a novel long-lasting prostaglandin (PG) I2 mimetic with inhibitory activity on thromboxane (TX) A2 synthase. This drug can also induce endogenous prostaglandin (PG)I2 and PGE2 levels. Furthermore, ONO-1301 acts as a cytokine inducer and can initiate tissue repair in a variety of diseases, such as pulmonary hypertension, pulmonary fibrosis, cardiac infarction, and obstructive nephropathy. In this study, our aim was to evaluate the effect of ONO-1301 on liver inflammation and fibrosis in a mouse model of non-alcoholic steatohepatitis (NASH). METHODS: The therapeutic effects of ONO-1301 against liver damage, fibrosis, and occurrence of liver tumors were evaluated using melanocortin 4 receptor-deficient (Mc4r-KO) NASH model mice. The effects of ONO-1301 against macrophages, hepatic stellate cells, and endothelial cells were also evaluated in vitro. RESULTS: ONO-1301 ameliorated liver damage and fibrosis progression, was effective regardless of NASH status, and suppressed the occurrence of liver tumors in Mc4r-KO NASH model mice. In the in vitro study, ONO-1301 suppressed LPS-induced inflammatory responses in cultured macrophages, suppressed hepatic stellate cell (HSC) activation, upregulated vascular endothelial growth factor (VEGF) expression in HSCs, and upregulated hepatocyte growth factor (HGF) and VEGF expression in endothelial cells. CONCLUSIONS: The results of our study highlight the potential of ONO-1301 to reverse the progression and prevent the occurrence of liver tumors in NASH using in vivo and in vitro models. ONO-1301 is a multidirectional drug that can play a key role in various pathways and can be further analyzed for use as a new drug candidate against NASH.

DOI： 10.1186/s41232-021-00191-6

PubMed

researchmap

Simultaneous muscular hemorrhages in two regions three years after successfully controlling refractory ascites using transjugular intrahepatic portosystemic shunt treatment: a case report.

Hiroteru Kamimura, Michitaka Imai, Hiroyuki Abe, Aiko Yoshioka, Kanae Hirose, Noriko Ishihara, Toru Ishikawa, Shuji Terai

Clinical journal of gastroenterology 2022年1月

記述言語：英語掲載種別：研究論文（学術雑誌）

INTRODUCTION: Various therapies and drugs have been developed to extend the life expectancy of patients with liver cirrhosis. The prolonged prognosis of cirrhotic patients may change the final cause of death in the future. Deep bleeding into the muscle is an uncommon but potentially life-threatening complication of liver cirrhosis. CASE REPORT: A 53-year-old man had undergone transjugular intrahepatic portosystemic shunt treatment for refractory ascites, which successfully controlled it for three years. However, he had started drinking again and experienced acute-on-chronic liver failure. He also had severe back pain. Abdominal computed tomography showed hyperdensities in the retroperitoneum and right pleural cavity. Despite blood infusion, he died from acute-on-chronic liver failure. A pathological autopsy revealed bleeding from the iliopsoas and right diaphragmatic muscle simultaneously, evident from the presence of red blood cells located between the muscle sheaths. Disruption of the small vessels in the skeletal muscle fibers was inferred. CONCLUSION: This is a critical case that underscores the significance of improving available knowledge based on the cause of final death of the patients with cirrhosis, who now have a good long-term prognosis owing to the latest medical developments.

DOI： 10.1007/s12328-022-01591-y

PubMed

researchmap

Use of a Deep Learning Approach for the Sensitive Prediction of Hepatitis B Surface Antigen Levels in Inactive Carrier Patients. 国際誌

Hiroteru Kamimura, Hirofumi Nonaka, Masaya Mori, Taichi Kobayashi, Toru Setsu, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

Journal of clinical medicine 11 ( 2 ) 2022年1月

記述言語：英語掲載種別：研究論文（学術雑誌）

Deep learning is a subset of machine learning that can be employed to accurately predict biological transitions. Eliminating hepatitis B surface antigens (HBsAgs) is the final therapeutic endpoint for chronic hepatitis B. Reliable predictors of the disappearance or reduction in HBsAg levels have not been established. Accurate predictions are vital to successful treatment, and corresponding efforts are ongoing worldwide. Therefore, this study aimed to identify an optimal deep learning model to predict the changes in HBsAg levels in daily clinical practice for inactive carrier patients. We identified patients whose HBsAg levels were evaluated over 10 years. The results of routine liver biochemical function tests, including serum HBsAg levels for 1, 2, 5, and 10 years, and biometric information were obtained. Data of 90 patients were included for adaptive training. The predictive models were built based on algorithms set up by SONY Neural Network Console, and their accuracy was compared using statistical analysis. Multiple regression analysis revealed a mean absolute percentage error of 58%, and deep learning revealed a mean absolute percentage error of 15%; thus, deep learning is an accurate predictive discriminant tool. This study demonstrated the potential of deep learning algorithms to predict clinical outcomes.

DOI： 10.3390/jcm11020387

PubMed

researchmap

患者まで届いている再生医療より効果のある肝硬変症に対する再生医療の実現を目指して

寺井崇二, 土屋淳紀, 渡邊雄介, 竹内卓, 野尻俊介, 酒井規裕, 木村成宏, 阿部寛幸

再生医療 21 ( 1 ) 20 - 23 2022年1月

記述言語：日本語出版者・発行元：(一社)日本再生医療学会

肝硬変症に対する治療として、2003年実施した臨床研究:自己骨髄細胞投与療法により、肝線維化改善とそれに引き続く肝再生の誘導、それに伴う肝機能の改善効果を確認してきた。その後、2017年より、肝硬変症に対する他家脂肪組織由来間葉系幹細胞投与療法の企業治験、現在軽症の肝硬変に対する他家脂肪組織由来間葉系幹細胞の医師主導治験を2021年より実施している。さらに2020年よりHMGB1ペプチドを用いた医師主導治験を実施しており、より効率のいい再生療法の開発を行っている。さらに次のステップとして間葉系幹細胞由来エクソソームを用いた治療の準備を行っている。本稿では、現時点における我々の肝硬変症に対するアプローチを紹介する。(著者抄録)

researchmap

Diet-related changes of basal lamina fenestrations in the villous epithelium of the rat small intestine: Statistical analysis on scanning electron microscopy.

Masatoshi Sato, Keisuke Morita, Rie Azumi, Yusuke Mizutani, Manabu Hayatsu, Tatsuo Ushiki, Shuji Terai

Biomedical research (Tokyo, Japan) 43 ( 1 ) 11 - 22 2022年

記述言語：英語掲載種別：研究論文（学術雑誌）

The epithelial basal lamina of the small intestine has numerous fenestrations for intraepithelial migration of leukocytes. We have reported dynamic changes of fenestrations in dietary conditions. To investigate this phenomenon, we performed statistical analyses using scanning electron microscopy images of the epithelial basal lamina of rat intestinal villi after removal of the villous epithelium by osmium maceration. We examined structural changes in the number and size of fenestrations in the rat jejunum and ileum under fasted and fed states for 24 h. Our findings revealed that, in the jejunum, the number of free cells migrating into the epithelium through fenestrations increased from 2 h after feeding, resulting in an increase in the fenestration size of intestinal villi; the number of free cells then tended to decrease at 6 h after feeding, and the fenestration size also gradually decreased. By contrast, the increase in the fenestration size by feeding was not statistically significant in the ileum. These findings indicate that the number of migrating cells increases in the upper part of the small intestine under dietary conditions, which may influence the absorption efficiency of nutrients including lipids, as well as the induction of nutrient-induced inflammation.

DOI： 10.2220/biomedres.43.11

PubMed

researchmap

Longitudinal increase in albumin-bilirubin score is associated with non-malignancy-related mortality and quality of life in patients with liver cirrhosis. 国際誌

Akira Sakamaki, Masaaki Takamura, Norihiro Sakai, Yusuke Watanabe, Yoshihisa Arao, Naruhiro Kimura, Toru Setsu, Hiroyuki Abe, Takeshi Yokoo, Hiroteru Kamimura, Shunsuke Tsubata, Nobuo Waguri, Toru Ishikawa, Hirokazu Kawai, Soichi Sugitani, Tomomi Sato, Kazuhiro Funakoshi, Masashi Watanabe, Kentarou Igarashi, Kenya Kamimura, Atsunori Tsuchiya, Yutaka Aoyagi, Shuji Terai

PloS one 17 ( 2 ) e0263464 2022年

記述言語：英語掲載種別：研究論文（学術雑誌）

Due to the developments in the treatment for hepatitis, it is possible to prevent the progression of liver fibrosis and improve patients' prognosis even if it has already led to liver cirrhosis (LC). Consequently, a two-step study was conducted. To begin with, a retrospective study was conducted to identify the potential predictors of non-malignancy-related mortality from LC. Then, we prospectively analyzed the validity of these parameters as well as their association with patients' quality of life. In the retrospective study, 89 cases were included, and the multivariate Cox regression analysis indicated that age (P = 0.012), model for end-stage liver disease (MELD) score (P = 0.012), and annual rate of change of the albumin-bilirubin (ALBI) score (P < 0.001) were significantly associated with LC prognosis. In the prospective study, 70 patients were included, and the patients were divided into cirrhosis progression and non-progression groups. The univariate logistic regression analysis indicated the serum procollagen type III N-terminal peptide level (P = 0.040) and MELD score (P = 0.010) were significantly associated with the annual rate of change of the ALBI score. Furthermore, the mean Chronic Liver Disease Questionnaire score worsened from 5.3 to 4.9 in the cirrhosis progression group (P = 0.034). In conclusion, a longitudinal increase in the ALBI score is closely associated with non-malignancy-related mortality and quality of life.

DOI： 10.1371/journal.pone.0263464

PubMed

researchmap

Esophageal Diverticulum - Indications and Efficacy of Therapeutic Endoscopy.

Hiroki Sato, Manabu Takeuchi, Kazuya Takahashi, Ken-Ichi Mizuno, Koichi Furukawa, Akito Sato, Nao Nakajima, Junji Yokoyama, Shuji Terai

Internal medicine (Tokyo, Japan) 61 ( 7 ) 943 - 949 2022年

記述言語：英語掲載種別：研究論文（学術雑誌）

Objective Esophageal diverticulum is rare, and the concomitance of esophageal motility disorders (EMDs) and the efficacy of novel endoscopic treatment have not been investigated in Japan. Methods An examination including high-resolution manometry (HRM) was performed for patients with both EMDs and epiphrenic diverticulum. EMD-related epiphrenic diverticulum and Zenker's diverticulum were treated using salvage peroral endoscopic myotomy (s-POEM) and endoscopic diverticulotomy, respectively. Results Six cases of epiphrenic diverticulum were diagnosed in this study. Among 125 patients with achalasia and spastic disorders, concomitant epiphrenic diverticulum was observed in 4 (3.2%). Of these, three showed a normal lower esophageal sphincter pressure on HRM, although gastroscopy and esophagography revealed typical findings of an impaired lower esophageal sphincter relaxation. These four patients were successfully treated with s-POEM, and the Eckardt score improved from 6.3 to 0.25 at 32.5 (range: 13-56) months of follow-up, with equivalent treatment efficacy to that observed for achalasia and spastic disorders without epiphrenic diverticulum. In contrast, the two remaining cases of epiphrenic diverticulum had normal esophageal motility. Six cases of Zenker's diverticulum were diagnosed, and endoscopic diverticulotomy was successfully performed in all. The dysphagia score decreased from 2.8 to 0.17 at 14.8 (range: 2-36) months of follow-up. Overall, 12 endoscopic treatments were performed for esophageal diverticulum; no adverse events were observed. Conclusion In epiphrenic diverticulum patients, concomitant EMDs are not rare and should be carefully diagnosed. A normal lower esophageal sphincter pressure on HRM does not always mean a normal lower esophageal sphincter relaxation. S-POEM and endoscopic diverticulotomy are effective minimally invasive treatment options for EMD-related epiphrenic diverticulum and Zenker's diverticulum.

DOI： 10.2169/internalmedicine.8196-21

PubMed

researchmap

Endoscopic Submucosal Dissection for Gastric Tube Carcinoma after Esophagectomy Contributes to Long-Term Outcomes. 国際誌

Satoru Hashimoto, Hiroki Sato, Ken-Ichi Mizuno, Kazuya Takahashi, Masafumi Takatsuna, Junji Yokoyama, Hiroshi Ichikawa, Manabu Takeuchi, Masaaki Kobayashi, Shuji Terai

Canadian journal of gastroenterology & hepatology 2022 1631415 - 1631415 2022年

記述言語：英語掲載種別：研究論文（学術雑誌）

The incidence of gastric tube carcinoma (GTC) after esophagectomy for esophageal carcinoma has increased in recent years. Surgical removal of the reconstructed gastric tube is associated with high mortality, and endoscopic submucosal dissection (ESD) is a promising alternative. There are limited reports of ESD for GTC. This study investigated the efficacy and safety of ESD in GTC. This single-center retrospective study examined patients who underwent ESD for GTC after esophagectomy at our institution between 2003 and 2018. The curability of GTC with ESD was evaluated histologically according to the Japanese Gastric Cancer Treatment Guidelines. Patient characteristics and procedural and long-term outcomes were analyzed. Overall, 31 patients (29 men and 2 women; median age, 73 years) with 45 GTC lesions underwent ESD. The mean period between primary esophagectomy and the diagnosis of GTC was 10.6 years. Bleeding during ESD was noted in two patients (6.5%). No other adverse or fatal events such as perforation were noted. Complete resection and curative resection were documented in 80.6% and 48.4% of cases, respectively. The 3-year and 5-year overall survival rates were 67.6% and 47.7%, respectively. The 3-year and 5-year disease-specific survival rates were 100% and 92.9%, respectively. One patient died of GTC, and fourteen patients died of other diseases, including primary carcinoma in five cases. ESD was safe and provided good long-term outcomes in patients with GTC. Regular long-term gastroscopy is required for the early detection of GTC. Patients with GTC after esophagectomy for esophageal carcinoma have a high risk of other primary carcinomas or comorbidities after ESD.

DOI： 10.1155/2022/1631415

PubMed

researchmap

Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function. 国際誌

Kunihiko Yokoyama, Akira Sakamaki, Kazuya Takahashi, Takumi Naruse, Chihiro Sato, Yuzo Kawata, Kentaro Tominaga, Hiroyuki Abe, Hiroki Sato, Atsunori Tsuchiya, Kenya Kamimura, Masaaki Takamura, Junji Yokoyama, Shuji Terai

PloS one 17 ( 2 ) e0264459 2022年

記述言語：英語掲載種別：研究論文（学術雑誌）

Overt hepatic encephalopathy (HE) is one of the complications of liver cirrhosis (LC), which negatively affects the prognosis and quality of life of patients. Small intestinal bacterial overgrowth (SIBO) is significantly associated with LC and its complications, including HE. We investigated the relationship between SIBO and LC, and the difference between hydrogen-producing and methane-producing SIBO (H-SIBO and M-SIBO, respectively). This is a prospective cohort study of 107 cases. Breath measurements of hydrogen and methane concentrations were performed for the diagnosis of SIBO. The study cohort included 81 males with a median age of 70 (40-86) years, and SIBO was detected in 31 cases (29.0%). There were no significant differences between the SIBO positive and SIBO negative groups. Reclassification into H-SIBO (16 cases) and others (91 cases) was performed, and the Child-Pugh score was only derived in the multivariate logistic analysis (P = 0.028, odds ratio 1.39, 95% confidence interval 1.04-1.85). Furthermore, H-SIBO was significantly associated with covert HE in chi-square test (50.0% vs. 24.2%, P = 0.034). In addition, we evaluated the therapeutic response on SIBO of rifaximin in eight covert HE patients. 20% patients with M-SIBO and 67% patients with H-SIBO showed an improvement of the breath test. In conclusion, H-SIBO, but not M-SIBO, is significantly associated with liver function, and rifaximin might be more effective for covert HE with H-SIBO. Therefore, the diagnosis of SIBO, including the classification as H-SIBO and M-SIBO, might help to determine the choice of treatment for HE.

DOI： 10.1371/journal.pone.0264459

PubMed

researchmap

Tahata, Y., Hikita, H., Mochida, S., Enomoto, N., Kawada, N., Kurosaki, M., Ido, A., Miki, D., Yoshiji, H., Takikawa, Y., Sakamori, R., Hiasa, Y., Nakao, K., Kato, N., Ueno, Y., Yatsuhashi, H., Itoh, Y., Tateishi, R., Suda, G., Takami, T., Nakamoto, Y., Asahina, Y., Matsuura, K., Yamashita, T., Kanto, T., Akuta, N., Terai, S., Shimizu, M., Sobue, S., Miyaki, T., Moriuchi, A., Yamada, R., Kodama, T., Tatsumi, T., Yamada, T., Takehara, T.

Journal of Gastroenterology 57 ( 2 ) 2022年

Tumor-to-tumor metastasis of colon cancer metastasizing to a pancreatic neuroendocrine tumor associated with von Hippel-Lindau disease: a case report

Natsui, H., Kohisa, J., Yoshikawa, S., Takeuchi, M., Yagi, R., Minagawa, M., Tani, T., Usuda, H., Terai, S.

Clinical Journal of Gastroenterology 15 ( 6 ) 2022年

Small extracellular vesicles and liver diseases: From diagnosis to therapy

Tsuchiya, A., Natsui, K., Ishii, Y., Koseki, Y., Takeda, N., Tomiyoshi, K., Yamazaki, F., Yoshida, Y., Terai, S.

World Journal of Hepatology 14 ( 7 ) 2022年

Prognostic study of acute-on-chronic liver failure patients Usefulness of the fibrosis-4 index

Watanabe, Y., Osaki, A., Waguri, N., Tsuchiya, A., Terai, S.

Medicine (United States) 101 ( 44 ) 2022年

Small G1 type III gastric neuroendocrine cell tumor showing scirrhous invasion and lymph node metastasis

Sato, A., Sato, Y., Oka, H., Honda, Y., Terai, S.

Gastrointestinal Endoscopy 95 ( 1 ) 2022年

Two cases of portal-systemic encephalopathy caused by multiple portosystemic shunts successfully treated with percutaneous transhepatic obliteration

Watanabe, Y., Osaki, A., Yamazaki, S., Yamazaki, H., Kimura, K., Takaku, K., Sato, M., Waguri, N., Terai, S.

Clinical Journal of Gastroenterology 15 ( 5 ) 2022年

Needle tract seeding after endoscopic ultrasound-guided tissue acquisition of pancreatic tumors: Nationwide survey in Japan

Kitano, M., Yoshida, M., Ashida, R., Kita, E., Katanuma, A., Itoi, T., Mikata, R., Nishikawa, K., Matsubayashi, H., Takayama, Y., Kato, H., Takenaka, M., Ueki, T., Kawashima, Y., Nakai, Y., Hashimoto, S., Shigekawa, M., Nebiki, H., Tsumura, H., Okabe, Y., Ryozawa, S., Harada, Y., Mitoro, A., Sasaki, T., Yasuda, H., Miura, N., Ikemoto, T., Ozawa, E., Shioji, K., Yamaguchi, A., Okuzono, T., Moriyama, I., Hisai, H., Fujita, K., Goto, T., Shirahata, N., Iwata, Y., Okabe, Y., Hara, K., Hashimoto, Y., Kuwatani, M., Isayama, H., Fujimori, N., Masamune, A., Hatamaru, K., Shimokawa, T., Okazaki, K., Takeyama, Y., Yamaue, H., Abue, M., Aiura, K., Akashi, T., Akiyama, T., Aoyagi, H., Araki, M., Arizumi, T., Aruga, Y., Asada, M., Asai, S., Baba, T., Ban, S., Chinen, K., Doi, S., Eguchi, T., Endo, M., Endo, S., Ezaki, T., Fujii, K., Fujii, M., Fujimori, M., Fujimoto, Y., Fujita, Y., Fujita, Y., Fukasawa, M., Fukuba, N., Fukuchi, S., Fukuda, K., Furukawa, M., Furumatsu, K., Hakamada, K., Hanada, K., Harada, K., Harano, M., Hashigo, S., Hashiguchi, K., Hayashi, K., Hayashi, N., Hayatsu, S., Hijioka, S., Hirano, A., Hirao, M., Hirooka, Y., Hirota, M., Horino, K., Hotta, Y., Ijima, M., Ikuta, Y., Imakiire, K., Imamura, T., Inatomi, O., Inoue, T., Irisawa, A., Ishida, E., Ishihara, K., Ishii, S., Ishii, T., Ito, H., Ito, J., Ito, T., Iwahashi, K., Iwano, H., Iwasaki, E., Iwashita, T., Iwata, K., Kakimoto, T., Kaku, T., Kamochi, J., Kanamori, A., Kaneto, H., Karasaki, H., Kato, Y., Kawaguchi, Y., Kawakami, H., Kawase, T., Kawashima, H., Kikuyama, M., Kimura, K., Kimura, T., Kitamura, K., Kobashigawa, K., Kobayashi, A., Kobayashi, K., Kobayashi, M., Kodama, R., Kodama, Y., Koike, Y., Komaki, T., Komura, T., Kondo, H., Kondo, H., Koshita, S., Koya, T., Ku, Y., Kuriyama, K., Kuroda, T., Kuroki, M., Kuroki, T., Kushiyama, Y., Maekawa, H., Makino, N., M, ai, K., Maruyama, H., Maruyama, M., Matsubara, S., Matsumoto, R., Matsunaga, K., Matsusaki, S., Matsushita, A., Mihara, M., Miyaike, J., Miyata, H., Miyoshi, H., Mizuno, S., Morita, T., Mouri, T., Mukai, T., Murakami, K., Nagano, H., Nakahara, K., Nakahara, O., Nakai, Y., Nakaji, S., Nakajima, J., Nakanishi, F., Nakano, Y., Nakashima, S., Naota, H., Nishida, N., Nishide, T., Nishikiori, H., Nomura, Y., Ochi, Y., Ochiai, T., Oe, S., Ogura, T., Ohata, A., Ohshima, T., Ohtsubo, K., Oka, H., Okazaki, A., Okochi, O., Onishi, Y., Otsuka, Y., Sagami, R., Sakakihara, I., Sakata, T., Sasahira, N., Sasaki, A., Sato, H., Sato, S., Sato, T., Satoh, A., Sekine, M., Sen-yo, M., Serikawa, M., Shibuya, H., Shimizu, S., Shinzato, M., Shitani, M., Suda, T., Sugimori, K., Sumi, H., Suzuki, N., Suzuki, R., Suzuki, Y., Tadauchi, A., Takahashi, K., Takahashi, K., Takaya, H., Takeda, Y., Takeda, O., Takihara, H., Tanaka, Y., Tanno, S., Tawada, K., Taya, Y., Terai, S., Terauchi, T., Togashi, J., Toki, M., Toyama, T., Tsuda, H., Tsugeno, H., Tsutsui, S., Uchida, K., Ueki, T., Usuba, T., Uza, N., Wakiyama, S., Watanabe, M., Yagi, Y., Yamada, R., Yamamoto, R., Yamazaki, M., Yasuda, I., Yawata, A., Yokota, T., Yokoyama, K., Yoshida, K., Yoshikawa, S., Yoshikawa, T.

Digestive Endoscopy 34 ( 7 ) 2022年

　前のページ - 次のページ　

<寺井 崇二>

論文 - 寺井 崇二

<寺井　崇二>

論文 - 寺井　崇二